home / stock / aytu / aytu articles
MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Eme...
MIAMI, Dec. 06, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emer...
MIAMI, Dec. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emer...
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing...
News, Short Squeeze, Breakout and More Instantly...
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA 1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2...
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December...